Preliminary clinical outcomes of one patient with non-Hodgkin’s lymphoma (NHL) and two patients with multiple myeloma (MM) treated with GM-CSF/TCR KO CAR-T cells demonstrated that CRISPR/Cas9-mediated ablation of GM-CSF/TCR had no adverse effect on CAR-T cell proliferation in these patients [251]. The gene discussed is CSF2; the disease is plasma cell myeloma.